Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TG Therapeutics Inc (TGTX) vs Unilever plc (UL) Price & Performance

TG Therapeutics IncTrade
Unilever plcTrade

Price performance (Past 24H)

Key statistics

TG Therapeutics Inc vs Unilever plc — how do they compare? TG Therapeutics Inc trades at $49.63 (market cap $7.64B), while Unilever plc trades at $61.65 (market cap $134.06B). The key difference: Unilever plc is far larger — about 17.5× TG Therapeutics Inc's market cap, and Unilever plc pays a 3.65% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

TGTXUL
Market Cap
$7.64B$134.06B
Sector
HealthConsumer Staples
52-Week High
$59.06$74.59
52-Week Low
$26.94$55.05
Enterprise Value
$7.84B$159.86B
Dividend Yield
3.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

Unilever plc

Unilever (UL) trades at $61.75, down 1.77% on the day, with a bearish technical signal. The stock shows strong profitability with a net income margin of 18.75% and ROE of 53.32%, but recent quarters have seen EPS misses against expectations. A major development is the planned $65 billion merger with McCormick's food business, expected to close in 2027, which could reshape growth prospects.

Outlook is mixed: robust cash flow and dividend yield near 1.75% support income investors, but execution risks on the McCormick deal and volatile earnings pose challenges. Analysts are divided, with 51% hold ratings, reflecting uncertainty amid strategic shifts. The stock appeals for its defensive staples exposure but requires monitoring of integration progress.

Returns comparison

Trailing returns across standard periods

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX

About Unilever plc

Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years

Read more on UL